First-Ever PROTAC Drug Approved for Breast Cancer Treatment
The FDA has approved vepdegestrant (Veppanu) — the first drug of the proteolysis-targeting chimera (PROTAC) class for the treatment of ER+/HER2- breast cancer with ESR1 mutation. In the VERITAC-2 study, the drug reduced the risk of progression by 43% compared to fulvestrant.
PROTAC Revolution in Oncology: Why Vepdegestrant Approval Opens a New Era in Breast Cancer Therapy
Introduction
On May 1, 2026, the FDA approved vepdegestrant (brand name Veppanu) for the treatment of ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations — an event that goes far beyond a routine addition to the oncology arsenal. This is the first-ever drug of the PROTAC (PROteolysis TArgeting Chimera) class to achieve regulatory approval. Twenty-five years of fundamental research, initiated in 2001 by the laboratories of Craig Crews and Raymond Deshaies, culminated in the clinical validation of a fundamentally different approach: not to inhibit a pathological protein, but to completely destroy it using the cell's own disposal system. For thousands of women with progressive breast cancer who have exhausted endocrine therapy options, this offers a chance for additional months of disease control. And for the entire industry, it is proof that targeted protein degradation is transforming from a scientific concept into a commercial reality.
Event Details and Timeline
The FDA decision was announced more than a month before the scheduled PDUFA date (June 5, 2026) — the accelerated approval reflects the quality of the submitted clinical package. The drug was developed by Arvinas in partnership with Pfizer under an agreement signed in July 2021. Under the deal, Pfizer paid $650 million upfront and committed up to $1.4 billion in milestone payments, as well as investing $350 million in Arvinas equity.
The pivotal study VERITAC-2 (NCT05654623) was a randomized, open-label, active-controlled, multicenter trial involving 624 patients from 213 centers in 25 countries. The primary endpoint was progression-free survival (PFS) as assessed by an independent central review committee.
Results in the ESR1-mutant population (270 patients) were compelling: a 43% reduction in the risk of progression or death compared to fulvestrant (HR 0.57; 95% CI: 0.42–0.77; p=0.0001). Median PFS was 5.0 months in the vepdegestrant group versus 2.1 months in the fulvestrant group — a difference of 2.9 months. Objective response rate was 19% versus 4%, respectively. Overall survival data remain immature: at the time of analysis, only 16% of deaths had occurred in the study population.
The safety profile is characterized predominantly by grade 1–2 events: decreased white blood cells, elevated liver transaminases, musculoskeletal pain, fatigue, nausea, and QTc interval prolongation. The prescribing information includes a warning about the need for monitoring cardiac function and electrolyte balance before and during therapy.
Impact and Significance
For patients. ESR1 mutations arise as an acquired resistance mechanism after aromatase inhibitor therapy and are found in 40–50% of patients with ER+/HER2- metastatic breast cancer who have received endocrine therapy in combination with CDK4/6 inhibitors. This population typically responds poorly to subsequent treatment. Median PFS on fulvestrant was only 2.1 months — highlighting a high unmet need. The modest absolute gain of 2.9 months is clinically significant in this context, as it concerns heavily pretreated patients with limited options.
For science and industry. The main significance of vepdegestrant approval is the validation of the PROTAC mechanism itself. Unlike traditional small molecules that work on an occupancy-driven principle, PROTACs act as catalysts: one drug molecule can sequentially ubiquitinate multiple target protein molecules, directing them for degradation by the proteasome (event-driven mechanism). As noted in Nature Reviews Cancer, this allows overcoming limitations of classical inhibitors, including drug resistance and the inability to target proteins without convenient binding sites.
Regulatory success of PROTAC confirms the possibility of creating drugs against proteins previously considered "undruggable" — multidomain, intrinsically disordered, scaffold proteins. Arvinas already has a portfolio of PROTAC programs against LRRK2 (neurodegeneration), KRAS G12D (solid tumors), BCL6 (non-Hodgkin lymphoma), and other targets.
For the market. According to an analytical report, 2026 is becoming the "year of commercialization" for targeted protein degradation. Following vepdegestrant, iberdomide (BMS) — the first molecular glue (CELMoD) for multiple myeloma — is expected to be approved. Deal volume in the TPD space in 2024–2025 exceeded $70 billion annually, comparable to the early-stage dynamics of the antibody-drug conjugate market.
Arvinas shares rose to $10.27 after the announcement, giving the company a market capitalization of approximately $657 million. Analysts are divided in their assessments: BTIG raised its price target to $16, H.C. Wainwright maintained a "buy" rating with a target of $18, while Truist Securities kept a "hold" rating with a target of $10.
Key Stakeholder Reactions
Arvinas CEO Randy Teel called the approval "a milestone demonstrating that targeted protein degradation can translate into meaningful clinical impact." He emphasized that the success strengthens confidence in the prospects of the company's entire portfolio.
The commercialization structure deserves special attention: Arvinas and Pfizer announced their intention to engage a third party to bring the drug to market. This unconventional approach creates some execution risk but reflects a pragmatic division of competencies.
The competitive landscape is rapidly evolving. Veppanu joins Orserdu (elacestrant, FDA-approved in January 2023) and Inluriyo (imlunestrant, Eli Lilly, approved in September 2025) in the ESR1-mutated breast cancer indication. Meanwhile, AstraZeneca received a negative recommendation from the FDA advisory committee for camizestrant (6 votes against 3). Olema Pharmaceuticals continues a Phase III trial with palazestrant — a full antagonist and degrader of estrogen receptors.
Outlook and Conclusions
The approval of vepdegestrant is not a finish line but a starting point. The key question that will determine the long-term fate of the drug and the entire PROTAC class in oncology is overall survival data. As The Clinical Trial Vanguard notes, "the only number to watch is the OS HR from VERITAC-2. It will either confirm targeted degradation as a genuine therapeutic breakthrough or show that the PFS benefit in a heavily pretreated population does not translate into survival — which would change the entire investment landscape for degraders in oncology."
Combination studies are underway that could expand the therapeutic window. The PROTAC technology platform is no longer limited to oncology: Arvinas reported positive Phase I results for ARV-102 (LRRK2 degrader in Parkinson's disease), achieving approximately 50% reduction of target protein levels in cerebrospinal fluid.
A broader trend is the expansion of the technology into autoimmune diseases. As analysts note, companies Kymera and Monte Rosa are developing oral degraders that could compete with biologics. The TPD pipeline includes approximately 390 clinical and preclinical projects globally.
It is safe to say that May 1, 2026, will go down in biotechnology history as the day PROTACs ceased to be a "promising concept." The mechanism has proven its efficacy in patients, and the regulatory system has shown readiness to evaluate fundamentally new therapeutic modalities. Ahead lie mature survival data, combination trials, commercial launch, and competition with other degraders. But the main barrier has already been crossed: targeted protein degradation has moved from the lab into clinical practice.
— Editorial Team
